Trial Profile

Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; Trametinib (Primary)
Indications Craniopharyngioma
Focus Therapeutic Use
Acronyms Swecranio

Most Recent Events

12 Apr 2023 Planned initiation date (estimated date of first participant enrollement) changed from 15 Jan 2023 to 1 May 2023.
04 Jan 2023 Planned initiation date changed from 15 Oct 2022 to 15 Jan 2023.
17 Nov 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com